Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 7, 2011, Pages 3527-3533

  Kwara, Awewura ^a,b   Tashima, Karen T ^a,b   Dumond, Julie B ^c   Poethke, Pamela ^b   Kurpewski, Jaclyn ^b   Kashuba, Angela D M ^c   Court, Michael H ^d   Greenblatt, David J ^d  

^a BROWN UNIVERSITY   (United States)

^b MIRIAM HOSPITAL   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2B6; EFAVIRENZ; PREGNANE X RECEPTOR; RIFAMPICIN;

ADULT; AFRICAN AMERICAN; ALGORITHM; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CAUCASIAN; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP DISORDER; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; BENZOXAZINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; RIFAMPIN; YOUNG ADULT;

EID: 79959192907     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00980-10     Document Type: Article

References (43)

1. Belanger, A. S., et al. 2009. Glucuronidation of the antiretroviral drug efavirenz (EFV) by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine (AZT). Drug Metab. Dispos. 37:1793-1796.
2. Benedek, I. H., et al. 1998. Pharmacokinetic interaction between efavirenz (EFV) and rifampin (RIF) after multiple oral doses in healthy volunteers, abstr. 42280. 12th World AIDS Conference, Geneva, Switzerland, 28 June to 3 July 1998.
3. Brennan-Benson, P., R. Lyus, T. Harrison, M. Pakianathan, and D. Macallan. 2005. Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all. AIDS 19:1541-1543. (Pubitemid 41400701)
4. Cabrera, S. E., et al. 2008. Efavirenz-rifampicin interaction: therapeutic drug monitoring to efavirenz dosage optimization in HIV/TBC patients. AIDS 22:2549-2551.
5. CDER. 2003. Guidance for industry bioavailability and bioequivalence studies for orally administered drug products - general considerations. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Rockville, MD. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf.
6. Centers for Disease Control and Prevention. 2007. Managing drug interactions in the treatment of HIV-related tuberculosis. CDC, Atlanta, GA. http://www.cdc.gov/tb/publications/guidelines/TB-HIV-Drugs/PDF/tbhiv.pdf.
7. Clifford, D. B., et al. 2005. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann. Intern. Med. 143:714-721.
8. Cohen, K., et al. 2009. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir. Ther. 14:687-695.
9. Court, M. H., et al. 2003. Evaluation of 3′-azido-3′- deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab. Dispos. 31:1125-1133.
10. Csajka, C., et al. 2003. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin. Pharmacol. Ther. 73:20-30.
11. DiGiacinto, J. L., K. M. Chan-Tack, S. M. Robertson, K. S. Reynolds, and K. A. Struble. 2008. Are literature references sufficient for dose recommendations? An FDA case study of efavirenz and rifampin. J. Clin. Pharmacol. 48:518-523.
12. Faucette, S. R., et al. 2006. Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor. J. Pharmacol. Exp. Ther. 317:1200-1209.
13. Friedland, G., S. Khoo, C. Jack, and U. Lalloo. 2006. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J. Antimicrob. Chemother. 58:1299-1302.
14. Gatanaga, H., et al. 2007. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin. Infect. Dis. 45:1230-1237.
15. Gatanaga, H., and S. Oka. 2009. Successful genotype-tailored treatment with small-dose efavirenz. AIDS 23:433-434.
16. Kwara, A., et al. 2009. Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J. Clin. Pharmacol. 49:1079-1090.
17. Kwara, A., M. Lartey, K. W. Sagoe, and M. H. Court. 2011. Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy. AIDS 25:388-390.
18. Kwara, A., M. Lartey, K. W. Sagoe, E. Kenu, and M. H. Court. 2009. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS 23:2101-2106.
19. Kwara, A., M. Lartey, K. W. Sagoe, N. L. Rzek, and M. H. Court. 2009. CYP2B6 (c.516G→T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br. J. Clin. Pharmacol. 67:427-436.
20. Kwara, A., et al. 2008. Pharmacokinetics of efavirenz when coadministered with rifampin in TB/HIV coinfected patients: pharmacogenetic effect of CYP2B6 variation. J. Clin. Pharmacol. 48:1032-1040.
21. Lamba, V., et al. 2003. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J. Pharmacol. Exp. Ther. 307:906-922.
22. Loboz, K. K., et al. 2006. Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin. Pharmacol. Ther. 80:75-84.
23. Lopez-Cortes, L. F., et al. 2006. Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen. J. Antimicrob. Chemother. 58: 1017-1023.
24. Lopez-Cortes, L. F., et al. 2002. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin. Pharmacokinet. 41:681-690.
25. Manosuthi, W., et al. 2006. Efavirenz 600 mg/day versus efavirenz 800 mg/ day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS 20:131-132. (Pubitemid 41818129)
26. Manosuthi, W., et al. 2009. Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin. Antimicrob. Agents Chemother. 53:4545-4548.
27. Manosuthi, W., et al. 2005. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. AIDS 19:1481-1486. (Pubitemid 41400693)
28. Marzolini, C., et al. 2001. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15:71-75. (Pubitemid 32055781)
29. Matteelli, A., et al. 2007. Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients. Curr. HIV Res. 5:349-353.
30. Ogburn, E. T., D. R. Jones, A. R. Masters, C. Xu, Y. Guo, and Z. Desta. 2010. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 (CYP) 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab. Dispos. 38: 1218-1229.
31. Oleson, L., L. L. von Moltke, D. J. Greenblatt, and M. H. Court. 2010. Identification of polymorphisms in the 3′-untranslated region of the human pregnane X receptor (PXR) gene associated with variability in cytochrome P450 3A (CYP3A) metabolism. Xenobiotica 40:146-162.
32. Panel on Antiretroviral Guidelines for Adults and Adolescents. 2011. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, Washington, DC. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
33. Pozniak, A. L., et al. 2005. BHIVA treatment guidelines for tuberculosis (TB)/HIV infection 2005. HIV Med. 6(Suppl. 2):62-83. (Pubitemid 41038586)
34. Ramachandran, G., et al. 2009. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India. Antimicrob. Agents Chemother. 53:863-868.
35. Ren, Y., et al. 2009. Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. J. Acquir. Immune Defic. Syndr. 50:439-443.
36. Rezk, N. L., R. D. Crutchley, R. F. Yeh, and A. D. Kashuba. 2006. Full validation of an analytical method for the HIV-protease inhibitor atazanavir in combination with 8 other antiretroviral agents and its applicability to therapeutic drug monitoring. Ther. Drug Monit. 28:517-525.
37. Ribaudo, H. J., et al. 2010. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J. Infect. Dis. 202:717-722.
38. Stahle, L., L. Moberg, J. O. Svensson, and A. Sonnerborg. 2004. Efavirenz plasma concentrations in HIV-infected patients: inter-and intraindividual variability and clinical effects. Ther. Drug Monit. 26:267-270.
39. Stohr, W., et al. 2008. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir. Ther. 13:675-685.
40. Uttayamakul, S., et al. 2010. Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults. AIDS Res. Ther. 7:8.
41. van Luin, M., et al. 2009. Efavirenz dose reduction to 200 mg once daily in a patient treated with rifampicin. AIDS 23:742-744.
42. Ward, B. A., et al. 2003. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 306:287-300.
43. Wyen, C., et al., on behalf of the German Competence Network for HIV/ AIDS. 2009. Association of a constitutive androstane receptor polymorphism (rs2307424) with treatment discontinuation in HIV+ patients receiving efavirenz, abstr. PS12/6. 12th European AIDS Conference, 11 to 14 November 2009, Cologne, Germany. http://onlinelibrary.wiley.com/doi/10.1111/j.1468-1293.2009.00789.x/ pdf.